# Ruxolitinib Treatment in Inclusion Body Myositis

> **NCT06536166** · PHASE2 · RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 80 (estimated)

## Conditions studied

- Inclusion Body Myositis, Sporadic

## Interventions

- **DRUG:** Ruxolitinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06536166
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-27
- **Primary completion:** 2028-06-10
- **Final completion:** 2028-09-10
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06536166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06536166, "Ruxolitinib Treatment in Inclusion Body Myositis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06536166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*